Last Updated: September 28, 2026

OPTICROM Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Opticrom, and when can generic versions of Opticrom launch?

Opticrom is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in OPTICROM is cromolyn sodium. Eleven suppliers are listed for this compound. Additional details are available on the cromolyn sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Opticrom

A generic version of OPTICROM was approved as cromolyn sodium by SANDOZ on June 16^th, 1999.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for OPTICROM?
What are the global sales for OPTICROM?
What is Average Wholesale Price for OPTICROM?

Summary for OPTICROM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for OPTICROM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for OPTICROM

See the table below for patents covering OPTICROM around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Austria	269138		⤷ Start Trial
Belgium	678175		⤷ Start Trial
Switzerland	476720	Procédé de préparation de composés bis-chromonylés à activité pharmaceutique	⤷ Start Trial
Switzerland	481912	Procédé de préparation de dérivés de la chromone à activité pharmaceutique	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.